Funding news · Nov 12, 2026

BioWraptor Raises $1.5M Pre-Seed to Stabilize Biomolecules at Room Temperature

BioWraptor Closes $1.5M Pre-Seed Round

BioWraptor, a New York platform biotechnology company, has raised a $1.5 million pre-seed round. The funding date is November 12, 2026. Investors in the round include NY Ventures, Greg Haar, Anima x Alpha Star, SNOCAP, Berangere Marguet, Pascal Marguet, and Ryan Jeffery. No lead investor was specified.

What BioWraptor Does

BioWraptor stabilizes fragile biomolecules at room temperature. Its approach uses naturally derived, tardigrade-inspired building blocks that form a protective wrap around biomolecules. The company aims to remove cold-chain dependence for research tools, diagnostics, medicines, and other biologics.

BioWraptor was founded by Maeva Coste and Jen Laws. Its approach builds on biomolecular stabilization research published by Coste and a City University of New York team in Nature Materials. The company is based in Long Island City, Queens, and participates in programs including Activate, NYCEDC Newlab Founder Fellows, and BioTools Innovator.

Funding Details

  • Round type: Pre-Seed
  • Funding amount: $1,500,000
  • Currency: USD
  • Funding date: November 12, 2026
  • Investors: NY Ventures, Greg Haar, Anima x Alpha Star, SNOCAP, Berangere Marguet, Pascal Marguet, Ryan Jeffery
  • Lead investor: Not specified

Strategic Context

Cold-chain dependence is a persistent constraint for biologics, diagnostics, and research tools, which typically require controlled temperature conditions for storage and transport. BioWraptor's tardigrade-inspired stabilization approach targets that constraint by wrapping fragile biomolecules with naturally derived building blocks to preserve them at room temperature.

The company's scientific foundation rests on research published in Nature Materials by founder Maeva Coste and a City University of New York team. Its participation in Activate, NYCEDC Newlab Founder Fellows, and BioTools Innovator places it within New York's early-stage biotech ecosystem.

Acquisition Relevance

At the pre-seed stage, BioWraptor represents an early position in biomolecule stabilization technology with potential application across research tools, diagnostics, medicines, and other biologics. The company's platform orientation and published research base are relevant to acquirers tracking cold-chain reduction technologies. The $1.5 million round, backed by NY Ventures and a group of individual and institutional investors, provides early capital to advance the platform. No lead investor was named, and the round size reflects the company's pre-seed stage.

© 2026 VeilStrat. All rights reserved.All systems operational